World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   243 records for 44 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5
Recruitment statusProspective RegistrationMain ID Public TitleDate of Registration
RecruitingYesNCT02988102
Role of Concentration of Biomarkers S100B and NSE in Serum in Mild and Moderate Head Trauma
06/12/2016
AuthorisedYesEUCTR2014-004851-30-NL
Efficacy and safety study to compare gabapentin versus tramadol in paediatric patients affected by cronic moderate to severe pain
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2014-004851-30-GREfficacy and safety study to compare gabapentin versus tramadol in paediatric patients affected by cronic moderate to severe pain10/11/2016
02/05/2016
Not recruitingYesNCT02722603
Study to Compare Gabapentin to Tramadol in Children
18/03/2016
Not recruitingYesNCT02709408
European Prospective Cohort Study on Enterobacteriaceae Showing Resistance to Carbapenems
02/03/2016
RecruitingYesISRCTN74074706
Multi-centre European study of major infectious disease syndromes - Arboviral compatible febrile illness
21/01/2016
RecruitingYesISRCTN91737921
ODYSSEY: Once daily Dolutegravir in Young people vS Standard thErapY 08/08/2014
 YesPER-074-13
ASSESS THE EFFICACY/SAFETY OF INTRAVITREAL RANIBIZUMAB IN PEOPLE WITH VISION LOSS DUE TO CHOROIDAL NEOVASCULARIZATION
14/04/2014
AuthorisedYesEUCTR2013-000087-29-IT
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-000087-29-SIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.03/09/2013
AuthorisedEUCTR2013-000087-29-LVInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.02/09/2013
AuthorisedEUCTR2013-000087-29-GRInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.21/10/2013
AuthorisedEUCTR2013-000087-29-ESInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.12/07/2013
AuthorisedEUCTR2013-000087-29-SEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.29/10/2013
AuthorisedEUCTR2013-000087-29-FRInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.16/09/2015
AuthorisedEUCTR2013-000087-29-FIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.30/07/2013
AuthorisedEUCTR2013-000087-29-LTInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.28/01/2014
AuthorisedEUCTR2013-000087-29-EEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.10/10/2013
AuthorisedEUCTR2013-000087-29-BEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.13/01/2014
AuthorisedEUCTR2013-000087-29-SKInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.07/11/2013
AuthorisedEUCTR2013-000087-29-DEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.08/07/2013
AuthorisedEUCTR2013-000087-29-PTInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.30/09/2013
AuthorisedEUCTR2013-000087-29-IEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukaemia.12/09/2013
AuthorisedEUCTR2013-000087-29-PLInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.04/11/2013
Not recruitingNCT01905943A Safety And Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participant With Chronic Lymphocytic Leukemia19/07/2013
02/07/2013
Not RecruitingYesEUCTR2012-003138-17-AT
A comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer
Recruitment statusMain IDPublic titleDate of registration
Not RecruitingEUCTR2012-003138-17-FIClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer20/05/2013
Not RecruitingEUCTR2012-003138-17-IEA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer.03/05/2013
Not RecruitingEUCTR2012-003138-17-LTA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer26/04/2013
AuthorisedEUCTR2012-003138-17-GBA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer08/05/2013
Not recruitingNCT01860638A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma21/05/2013
Not RecruitingEUCTR2012-003138-17-BGA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer10/06/2013
Not RecruitingEUCTR2012-003138-17-ITClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer03/05/2013
Not RecruitingEUCTR2012-003138-17-LVA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer10/05/2013
Not RecruitingEUCTR2012-003138-17-EEA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer08/05/2013
Not RecruitingEUCTR2012-003138-17-HRClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer21/10/2014
Not RecruitingEUCTR2012-003138-17-ESA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer16/05/2013
Not RecruitingEUCTR2012-003138-17-SEClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer30/05/2013
Not RecruitingEUCTR2012-003138-17-PTA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer04/06/2013
Not RecruitingEUCTR2012-003138-17-GRClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer25/06/2013
24/04/2013
RecruitingNoPER-051-12
A PHASE II PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SAFEHER STUDY]
12/12/2012
     
1 2 3 4 5
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.3 - Version history